ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells (Q39023473)

8 September 2017

ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells (English)

1 reference

8 September 2017

Giovanna Bossi

1

1 reference

8 September 2017

Sandrine Buisson

2

1 reference

8 September 2017

Joanne Oates

3

1 reference

8 September 2017

Bent K Jakobsen

4

1 reference

8 September 2017

Namir J Hassan

5

1 reference

8 September 2017

15 February 2014

1 reference

Cancer Immunology, Immunotherapy

8 September 2017

1 reference

8 September 2017

63

1 reference

8 September 2017

437-448

1 reference

8 September 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-014-1525-z

8 September 2017

0 references

cites work

Innate versus adaptive immunity: a paradigm past its prime?

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

The critical role of type-1 innate and acquired immunity in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Structural and biophysical determinants of αβ T-cell antigen recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Human TCR-binding affinity is governed by MHC class restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

High-affinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 or CDR3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Directed evolution of human T-cell receptors with picomolar affinities by phage display.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Stable, soluble T-cell receptor molecules for crystallization and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Monoclonal TCR-redirected tumor cell killing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Germ Line-governed Recognition of a Cancer Epitope by an Immunodominant Human T-cell Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Priming of T cells by exogenous antigen cross-presented on MHC class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Human macrophages and dendritic cells can equally present MART-1 antigen to CD8(+) T cells after phagocytosis of gamma-irradiated melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Dendritic cell immunization route determines CD8+ T cell trafficking to inflamed skin: role for tissue microenvironment and dendritic cells in establishment of T cell-homing subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Tumor antigen cross-presentation and the dendritic cell: where it all begins?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Dendritic cell dysfunction in cancer: a mechanism for immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Memory CD8+ T cells protect dendritic cells from CTL killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Dendritic cells acquire antigens from live cells for cross-presentation to CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

A role for class A scavenger receptor in dendritic cell nibbling from live cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Cross-dressed dendritic cells drive memory CD8+ T-cell activation after viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1525-Z

10.1007/S00262-014-1525-Z

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference